Optimism... Elsewhere... This taken from the MIR.V discussion board on yahoo financial "...MedMira has utilized its patented Rapid Vertical Flow (RVF) technology and developed the companys first rapid antigen test, VYRA CoV-2 Antigen Test (VYRA CoV-2), designed to detect SARS-CoV-2 virus in the swab samples. VYRA CoV-2 product expands the existing COVID-19 product family and directly addresses the wishes of our customers for an equally fast, reliable, and easy-to-use testing solution. VYRA CoV-2 saliva-based swab test is designed to be non-invasive and user-friendly, making this test more suitable for the home settings. The successful development of this test opens up a new product line that has been a pioneering step for MedMira, said Hermes Chan, CEO of MedMira. With this we offer customers our COVID-19 product bundle that can accommodate various testing needs. For example, the VYRA CoV-2 can used to determine if the person is infected; REVEALCOVID-19 PLUS [PLUS] tells if anti-SARS-CoV-2 antibodies are present; and our REVEALCOVID-19 Nab-Y [Nab-Y] neutralizing test can potentially identify if the individual is immune to the virus..." Another poster remarked that the million sold volume today is a million bought... We don't know all that is going on. Every good card player knows not to show their cards too soon... ... If ever... Sounds like HC et al have used the recent uptick in prosperity to add depth to their product line. Keep in mind, the market loves acquisitions... .. And MIR makes for a great acquisition target. The top return will be on a full slate of approved product.. Time will tell..